Mariana's acquisition: RAVen, radiopharma-ceuticals, and reflections on company-building

We are happy to announce that Novartis has acquired our portfolio company Mariana Oncology for $1B upfront and $750M in downstream milestones. Novartis has deep clinical and commercial experience with oncology and radiopharmaceuticals, and is well positioned to work with the Mariana team on advancing Mariana’s portfolio of radiopharmaceuticals into the clinic to improve outcomes for cancer patients. We look forward to the R&D we worked to seed bearing fruit for patients and society someday. 

This is the first acquisition of a fully-baked, “home-grown” company from RA Capital’s RAVen incubator, which builds companies that our venture team funds and helps govern, so we wanted to mark the occasion by sharing a bit more about how we got here.